Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of beta-catenin signaling

Although the development of drugs that control Ras is an emerging topic in cancer therapy, no clinically applicable drug is currently available. We have previously utilized knowledge of the Wnt/beta-catenin signaling-dependent mechanism of Ras protein stability regulation to identify small molecules that inhibit the proliferation and transformation of various colorectal cancer (CRC) cells via degradation of both beta-catenin and Ras. Due to the absence of Ras degradation in cells expressing a nondegradable mutant form of beta-catenin and the need to determine an alternative mechanism of Ras degradation, we designed a cell-based system to screen compounds that degrade Ras independent of the Wnt/beta-catenin signaling pathway. A cell-based high-content screening (HCS) system that monitors the levels of EGFP-K-Ras(G12V) was established using HCT-116 cells harboring a nondegradable mutant CTNNB1 (Delta S45). Through HCS of a chemical library composed of 10,000 compounds and subsequent characterization of hits, we identified several compounds that degrade Ras without affecting the beta-catenin levels. KY7749, one of the most effective compounds, inhibited the proliferation and transformation of CRC cells, especially KRAS-mutant cells that are resistant to the EGFR monoclonal antibody cetuximab. Small molecules that degrade Ras independent of beta-catenin may able to be used in treatments for cancers caused by aberrant EGFR and Ras.